ReviR Therapeutics Secures $30 Million Series A Funding to Advance AI-Driven Drug Development Platform

Biotech company ReviR Therapeutics has made significant progress in the field of innovative drug discovery, announcing the completion of A $30 million Series A funding round. The round was led by Lapam Capital, a well-known Investment institution, with active participation from existing investors such as CDH Investment, 5Y Capital and Yael Capital, China's leading private equity firms, and new investor XtalPi Inc. And the CMT Research Foundation (CMTRF) have also joined the investment lineup, demonstrating the industry's broad recognition and expectations for ReviR Therapeutics.

Since its founding in 2021, ReviR Therapeutics has been revolutionizing the field of drug discovery using artificial intelligence technology. The funds raised in this round will be used to accelerate the construction of VoyageR, its innovative AI drug discovery platform, which leverages advanced AI algorithms combined with the company's extensive experience in drug discovery to achieve breakthroughs in the treatment of neurological diseases such as Huntington's disease (HD). In addition, the funding will be used to accelerate the preclinical and clinical research process to bring innovative therapies to patients worldwide at an early date.

ReviR Therapeutics' international team consists of a group of experts with deep professional backgrounds who have developed a comprehensive AI platform and built a mature pipeline system. The company's research and development strategy focuses on the treatment of neurodegenerative diseases and hereditary rare diseases, and is strategically positioned through multiple self-developed pipelines. In particular, ReviR Therapeutics is based on the central principle to explore innovative therapies from the RNA level, using AI technology to design oral gene therapy, through small molecule drugs to regulate RNA, in order to achieve precision treatment at the gene level.

Dr. Li Yang, co-founder and Chairman of ReviR Therapeutics, said: "There are many types of neurological diseases and large patient populations worldwide, but unfortunately, most of them still lack effective treatments. ReviR Therapeutics is committed to disrupting this status quo, and we are developing oral gene therapies that aim to achieve gene regulation by regulating RNA, providing a more convenient and safe treatment option for the clinic. At present, the company has gradually moved from the early stage of platform construction to the clinical stage, we will continue to optimize the AI platform, and actively promote the pipeline into the clinical trial stage, in order to bring benefits to patients as soon as possible."

The success of this financing not only injected strong financial support for the future development of ReviR Therapeutics, but also set a new milestone in the field of AI-driven drug development. With the continuous optimization of the VoyageR platform and the deepening of clinical studies, ReviR Therapeutics is expected to achieve a major breakthrough in the treatment of neurological diseases, bringing new hope to patients worldwide.